SynthesisEndocrinology, diabetes & metabolism2026
The Effect of Empagliflozin on Renal Outcomes in Patients With Established Cardiovascular Disease: Systematic Review and Meta-Analysis of Randomised Placebo-Controlled Trials.
Synthesis in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmpagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), may be associated with improved renal outcomes. However, the magnitude and potential heterogeneity of effect among patients with cardiovascular disease (CVD) remain unclear. This systematic review aimed to evaluate the efficacy and safety of empagliflozin on renal outcomes in patients with established CVD.
methodsBased on the PRISMA guideline, we searched PubMed, Embase, Scopus Google Scholar, Cochrane Library and Web of Science databases, as well as study references, to find randomised controlled clinical trials (RCTs) that evaluated the effect of empagliflozin (regardless of dose) compared with placebo on renal outcomes in patients with CVD, with no time limit, up to 20 August 2025. Outcomes included kidney disease progression, composite renal outcome, nephropathy, doubling of serum creatinine and safety.
resultsThirteen RCTs involving 36,169 patients were included. A pooled analysis of 12 studies showed that empagliflozin was significantly associated with a reduced risk of progression of kidney disease (HR: 0.66, 95% CI: 0.58, 0.74, I
conclusionEmpagliflozin may significantly reduce the risk of CKD outcomes in patients with CVD compared with placebo. Empagliflozin also had a favourable safety profile. Empagliflozin can be prescribed as an effective and safe antidiabetic drug in patients with CVD to improve renal outcomes and prevent CKD progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.